Press releases
- Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy
- Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
- Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
- Calliditas Q1 report, January - March 2024
- In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
- Invitation to the presentation of Calliditas´s interim report January - March 2024
- Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
- Notice of annual general meeting of Calliditas Therapeutics AB (publ)
- Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
- Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
More ▼
Key statistics
As of last trade Calliditas Therapeutics AB (LC8:FRA) traded at 18.14, -1.25% below its 52-week high of 18.37, set on Jun 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.31 |
---|---|
High | 18.31 |
Low | 18.11 |
Bid | 18.18 |
Offer | 18.38 |
Previous close | 18.18 |
Average volume | 114.29 |
---|---|
Shares outstanding | 59.58m |
Free float | 49.57m |
P/E (TTM) | -- |
Market cap | 12.38bn SEK |
EPS (TTM) | -9.78 SEK |
Data delayed at least 15 minutes, as of Jun 10 2024 08:59 BST.
More ▼